A major public health milestone has been reached as a global cervical cancer vaccine push has saved an estimated 1.4 million lives, according to new data released by Gavi. The organization announced the results on Monday while marking World Cervical Cancer Elimination Day, highlighting the profound impact of HPV vaccination in low-income countries.
Strong Progress Through a Three-Year Initiative
Gavi reported that 86 million girls are now protected against HPV, the leading cause of cervical cancer. The gains came from a focused three-year campaign delivered through collaboration between Gavi, national governments, and global health partners. The effort targeted countries where immunization access has historically been limited, and where cervical cancer continues to cause some of the highest mortality rates.
Most low-income nations lack comprehensive screening systems, making vaccination the most effective front-line defense. These countries accounted for 90 percent of the 350,000 global cervical cancer deaths recorded in 2022, underscoring the urgency behind the expanded vaccine rollout.
Sharp Rise in Africa’s HPV Vaccine Coverage
Gavi noted remarkable progress across Africa, where coverage increased from only four percent in 2014 to 44 percent by the end of 2024. This figure surpasses Europe’s rate of 38 percent. The rapid growth reflects coordinated efforts to scale affordable vaccines, strengthen distribution systems, and increase public awareness.
Sania Nishtar, Gavi’s chief executive, praised the commitment shown by governments and implementing organizations. She said the achievement represents a powerful example of health equity in action, even as cervical cancer continues to claim a life every two minutes worldwide.
Lower Vaccine Costs Boost Access
The alliance also emphasized its strategy of using purchasing power to lower prices for low-income countries. Through long-term agreements with manufacturers, Gavi secured HPV vaccine doses priced between $2.90 and $5.18. Outside Gavi-supported programs, similar doses can cost $100 or more, placing them out of reach for many health systems.
This pricing shift allowed nearly 50 countries to integrate HPV vaccines into national immunization schedules, dramatically expanding access for young girls most at risk.
Single-Dose Guidance Accelerates Coverage
The World Health Organization supported a single-dose HPV vaccination schedule in 2022, making it possible to protect twice as many girls using existing vaccine supplies. This adjustment contributed to faster rollout, especially in regions with limited resources.
Gavi said the combined push of reduced pricing, streamlined schedules, and widespread government support is driving global momentum toward the long-term elimination of cervical cancer. The progress marks one of the clearest examples of how targeted vaccination efforts can transform public health outcomes for generations.
